Filing Analysis
Fate Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2026.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information is furnished under Item 2.02 and not filed for purposes of Section 18 liability.
Fate Therapeutics reported the results of its June 12, 2026 Annual Meeting of Stockholders. All proposals were approved, including the election of directors, ratification of Ernst & Young LLP as auditors, and an increase in the 2022 Stock Option and Incentive Plan.
🚩 Red Flags
- Significant opposition to the equity plan increase: 14,304,810 shares voted against the 7,000,000 share increase, representing a notable portion of the votes cast.
📋 Key Facts
- Stockholders approved an increase of 7,000,000 shares to the 2022 Stock Option and Incentive Plan.
- Three Class I Directors (Robert S. Epstein, Karin Jooss, and Laura J. Hamill) were elected to hold office until 2029.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Executive compensation received a non-binding advisory vote of approval.
- Total shares entitled to vote were 116,281,693, with 87,134,422 shares present or represented by proxy.
Fate Therapeutics Inc. filed an 8-K to disclose the update of its corporate presentation for use at meetings and conferences, specifically mentioning the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.
📋 Key Facts
- The filing date is June 4, 2026.
- The company updated its Corporate Presentation (Exhibit 99.1).
- The presentation is intended for use at the EULAR 2026 Congress.
Fate Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly update on the company's financial condition and results of operations.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 13, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was included as Exhibit 99.1 to the filing.
Fate Therapeutics, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release issued on February 26, 2026.
📋 Key Facts
- The report was filed on February 26, 2026, for the period ending December 31, 2025.
- The company furnished the financial results under Item 2.02 (Results of Operations and Financial Condition).
- The press release containing specific financial figures was included as Exhibit 99.1.
Fate Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on November 13, 2025.
📋 Key Facts
- The company reported financial results for the fiscal quarter ending September 30, 2025.
- The announcement was made via press release dated November 13, 2025 (Exhibit 99.1).
- The filing is pursuant to Item 2.02 of Form 8-K regarding Results of Operations and Financial Condition.
Fate Therapeutics announced clinical data updates for its FT819 CAR T-cell program in systemic lupus erythematosus (SLE) presented at the ACR Convergence 2025. The update highlights successful B-cell depletion and immune remodeling across different conditioning regimens.
📋 Key Facts
- 10 patients with treatment-refractory, moderate-to-severe SLE have been treated with FT819 as of a September 25, 2025 data cut-off.
- Data showed rapid and sustained CD19+ B cell depletion in patients receiving less-intensive conditioning (Regimen A).
- Patients on a conditioning-free regimen (Regimen B) also showed meaningful reduction in CD19+ B cells and improved disease activity scores.
- The company has initiated dose-expansion cohorts for AAV, IIM, and SSc indications.
- Fate is working with the FDA under RMAT designation to align on a registrational study design, aiming to start a pivotal study in 2026.
Fate Therapeutics announced the voluntary resignation of two board members and a reduction in board size, alongside the appointment of Kamal Adawi as the new Chief Financial Officer effective October 20, 2025.
🚩 Red Flags
- Simultaneous resignation of two board members.
- Reduction in the total number of Board seats (from 10 to 8).
📋 Key Facts
- John D. Mendlein, Ph.D., J.D. and Neelufar Mozaffarian, M.D., Ph.D. resigned from the Board effective October 13, 2025.
- Dr. Mozaffarian also resigned from the Nominating and Corporate Governance Committee and Science and Technology Committee.
- The Company's Board size decreased from ten (10) to eight (8) directors.
- Kamal Adawi appointed as CFO, Principal Financial Officer, and Principal Accounting Officer effective October 20, 2025.
- Mr. Adawi's compensation includes a $495,000 base salary, target bonus of 40%, 375,000 stock options, and 75,000 RSUs.
Fate Therapeutics announced a corporate restructuring involving a 12% workforce reduction to extend cash runway and reduce operating expenses. The company also released its financial results for the quarter ended June 30, 2025.
🚩 Red Flags
- Workforce reduction (RIF) often indicates liquidity or burn rate concerns in biotech companies.
- Explicit mention of the need to 'extend cash runway' suggests limited capital reserves.
📋 Key Facts
- Board of Directors approved a corporate restructuring on August 7, 2025.
- Workforce reduction (RIF) affects approximately 12% of total employees.
- Estimated restructuring charges: $0.9 million to $1.2 million in Q3 2025.
- Primary goals of restructuring are to streamline operations and extend cash runway.
- Financial results for the quarter ended June 30, 2025 were released on August 12, 2025.
This is an amended 8-K filing (8-K/A) regarding the results of Fate Therapeutics' 2025 annual meeting. The company is disclosing that stockholders approved a recommendation to hold non-binding advisory votes on executive compensation (Say-on-Pay) on an annual basis.
📋 Key Facts
- The filing amends a previous 8-K filed on May 30, 2025.
- Stockholders at the May 29, 2025 Annual Meeting voted to hold future non-binding advisory votes on executive compensation every year.
- The Board will follow this annual voting schedule until at least the 2031 annual meeting of stockholders.
Fate Therapeutics held its Annual Meeting of Stockholders on May 29, 2025, resulting in the election of three Class III directors and approval of several key corporate amendments. Notably, Matthew Abernethy was appointed to the Board and Audit Committee, replacing Timothy P. Coughlin.
🚩 Red Flags
- Significant increase in authorized share count (from 250M to 350M) and incentive plan pool may lead to future dilution.
- High 'Against' votes on the stock option plan amendment (16.9M against vs 51.4M for), suggesting shareholder skepticism regarding compensation/dilution.
📋 Key Facts
- Matthew Abernethy elected to the Board as a Class III director and member of the Audit Committee; term effective May 29, 2025.
- Timothy P. Coughlin's term on the Board and Audit Committee ended concurrently with Abernethy's election.
- Stockholders approved an increase in authorized Common Stock from 250,000,000 to 350,000,000 shares.
- Stockholders approved a second amendment to the 2022 Stock Option and Incentive Plan, increasing available shares by 7,000,000.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- Matthew Abernethy granted an option for 110,000 shares of Common Stock with a 36-month monthly vesting schedule.
Fate Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Signed by Bahram Valamehr, Ph.D., MBA, President and CEO.
Fate Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 5, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Fate Therapeutics announced the retirement of J. Scott Wolchko from all executive officer and director roles, effective December 31, 2024. Dr. Bahram Valamehr has been appointed to succeed him as President and CEO.
🚩 Red Flags
- Simultaneous departure of CEO and CFO (dual role vacancy).
- Significant ongoing cash outflow to a former executive via an advisory agreement ($675,000 annual base).
- Acceleration clauses in equity awards for the departing officer if terminated without cause.
📋 Key Facts
- J. Scott Wolchko retired as President, CEO, CFO, Treasurer, and principal accounting officer on Dec 31, 2024.
- Dr. Bahram Valamehr (previously President of R&D) appointed as successor effective Jan 1, 2025.
- The Company entered a strategic advisory agreement with Mr. Wolchko for one year (Jan 1, 2025 - Dec 31, 2025).
- Advisory compensation for Mr. Wolchko is $56,250 per month.
- The Advisory Agreement includes provisions for accelerated vesting of equity awards if terminated by the company without cause.
Fate Therapeutics announced the resignation of J. Scott Wolchko from his roles as Director, President, CEO, and CFO. He will transition to a strategic advisor role on December 31, 2024, with Bahram Valamehr, Ph.D., succeeding him as President and CEO effective January 1, 2025.
🚩 Red Flags
- Simultaneous departure of CEO and CFO (dual role vacancy).
- Leadership transition in the middle of the fiscal year/quarterly cycle.
📋 Key Facts
- J. Scott Wolchko resigns from the Board of Directors effective November 27, 2024.
- Mr. Wolchko will retire from his roles as President, CEO, and CFO on December 31, 2024.
- Bahram Valamehr, Ph.D., MBA (current President of R&D) to become President and CEO effective January 1, 2025.
- The company states the resignation was not due to any disagreement with policies, procedures, or practices.
- Mr. Wolchko will remain as a strategic advisor following his departure from executive roles.
Fate Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 12, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Fate Therapeutics, Inc. has entered into an Amended and Restated (A&R) Form of Indemnification Agreement with its current directors and officers. This agreement updates terms regarding change of control provisions, defense expense advancements, and specific performance rights.
🚩 Red Flags
- The inclusion of specific 'change of control' provisions and separate counsel expenses can sometimes be a precursor to M&A activity or management restructuring, though it is standard corporate governance practice.
📋 Key Facts
- Board approved the A&R Indemnification Agreement on August 26, 2024.
- The new agreement supersedes and replaces all previously adopted forms of indemnification agreements.
- Key updates include revised 'change of control' provisions regarding board composition changes.
- Includes coverage for an Indemnitee’s separate counsel expenses in change of control events.
- Clarifies that indemnification is independent of the availability of insurance coverage.
- Establishes an express presumption of good faith for Indemnitees, shifting the burden of proof to those seeking to overcome it.
Fate Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2024. The filing serves as a formal announcement of the release of their earnings press release.
📋 Key Facts
- The company announced financial results for the quarter ended June 30, 2024.
- The announcement was made via a press release dated August 13, 2024 (Exhibit 99.1).
- The filing is pursuant to Item 2.02 of Form 8-K regarding Results of Operations and Financial Condition.
Fate Therapeutics, Inc. announced the expansion of its Board of Directors from nine to ten members with the appointment of Neelufar Mozaffarian, M.D., Ph.D., as a Class II director.
📋 Key Facts
- Board size increased from 9 to 10 directors effective July 29, 2024.
- Dr. Neelufar Mozaffarian appointed to the Board and members of the NCG Committee and Science and Technology Committee.
- Dr. Mozaffarian granted an option to purchase 80,000 shares of common stock with a 36-month monthly vesting schedule.
- The exercise price for the options is set at the closing price on July 29, 2024.
Fate Therapeutics, Inc. announced that stockholders approved a Certificate Amendment to the company's Articles of Incorporation on June 7, 2024. The amendment allows for the exculpation of certain officers from personal liability.
🚩 Red Flags
- Exculpation clauses can sometimes be viewed as a way to shield management from accountability for certain breaches of fiduciary duty (duty of care).
📋 Key Facts
- Stockholders voted to approve the Certificate Amendment at the Annual Meeting held on June 7, 2024.
- The amendment allows for the exculpation of certain company officers.
- The Board had previously recommended this amendment in February 2024.
- The amendment became effective upon filing with the Delaware Secretary of State on June 7, 2024.
Fate Therapeutics announced the appointment of CEO J. Scott Wolchko as interim CFO following the resignation of Edward J. Dulac III. The filing also details the results of the company's Annual Meeting, including the approval of an expanded stock option plan and director elections.
🚩 Red Flags
- Sudden transition where the CEO assumes the CFO role, indicating potential immediate vacancy in financial leadership.
- Significant shareholder opposition (approx. 31M votes against) regarding the increase in shares for the stock option plan.
📋 Key Facts
- CEO J. Scott Wolchko appointed to succeed Edward J. Dulac III as CFO and principal financial officer, effective immediately (June 3, 2024).
- Edward J. Dulac III resigned from his position; resignation effective date is June 14, 2024.
- Stockholders approved an amendment to the 2022 Stock Option and Incentive Plan to increase available shares by 8,000,000.
- Ernst & Young LLP was ratified as the independent auditor for fiscal year ending Dec 31, 2024.
- Stockholders approved an amendment to the Certificate of Incorporation to include officer exculpation provisions.
Fate Therapeutics announced the voluntary resignation of its CFO, Edward J. Dulac III, effective June 14, 2024. The CEO, J. Scott Wolchko, will assume the role of CFO and principal financial officer upon the departure.
🚩 Red Flags
- Dual role for CEO: The CEO is assuming the CFO position, which can indicate resource constraints or a lack of immediate successor availability in a micro-cap/mid-cap biotech environment.
- Concentration of leadership: Having one individual serve as both President/CEO and CFO creates significant management bandwidth concerns.
📋 Key Facts
- Edward J. Dulac III resigned as CFO on May 30, 2024; effective date is June 14, 2024.
- Resignation was voluntary to pursue another opportunity and not due to any disagreement with the Company.
- J. Scott Wolchko (current President and CEO) will succeed Mr. Dulac as CFO and principal financial/accounting officer.
- Mr. Wolchko previously served as CFO of the company until August 2020.
Fate Therapeutics announced clinical progress for its FT819 program, including the first patient treated in a systemic lupus erythematosus (SLE) study and positive translational data from its B-cell malignancy study. The company also presented data regarding its FT522 CAR NK cell program at the ASGCT Annual Meeting.
📋 Key Facts
- First patient with SLE has been treated in the Phase 1 autoimmunity study of FT819.
- FT819 BCM study showed a favorable safety profile: no dose-limiting toxicities (DLTs), no ICANS, and no GvHD; only 14% incidence of low-grade (< Grade 2) CRS.
- In the Phase 1 BCM study for FT819, 17 patients with aggressive large B cell lymphoma showed a 47% overall response rate (ORR) and 24% complete response rate (CR).
- The company intends to focus further clinical development of FT819 exclusively in autoimmune diseases.
- FT522 data showed rapid, deep, and sustained B-cell depletion in the first two patients treated.
Fate Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results cover the quarter ended March 31, 2024.
- The report was filed on May 9, 2024.
Fate Therapeutics announced a dual-track financing consisting of a $74.7 million public common stock offering at $5.50 per share and a $20 million private placement of pre-funded warrants to an affiliate of director Michael Lee.
🚩 Red Flags
- Related-party transaction: The Redmile Group fund is affiliated with a Company director (Michael Lee) and is a significant stockholder.
- Significant dilution: Issuance of over 18 million total securities (shares + warrants) represents substantial potential dilution for existing shareholders.
📋 Key Facts
- Public Offering: 14,545,454 shares of common stock at $5.50 per share via underwriting agreement with BofA Securities, Jefferies, and Leerink Partners.
- Private Placement: Sale of pre-funded warrants to a fund affiliated with Redmile Group, LLC for up to $20 million.
- Pre-Funded Warrants: 3,636,364 warrants at a purchase price of $5.499 per warrant (exercise price of $0.001).
- Estimated Net Proceeds: Approximately $74.7 million from the public offering and $20 million from the private placement.
- Use of Proceeds: Funding clinical/nonclinical studies, manufacturing expenses for product candidates, R&D, and working capital.
- Closing Date: Expected March 21, 2024.
Fate Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: February 26, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing the financial results.